N-Zyme Advances Pepsin-Targeting Reflux Drug Into Phase 2 Trial
NEWARK, DE — N-Zyme Biomedical has begun a Phase 2 clinical trial of its lead drug candidate for laryngopharyngeal reflux, advancing a treatment approach that targets pepsin rather than stomach …
N-Zyme Advances Pepsin-Targeting Reflux Drug Into Phase 2 Trial Read More